Drugs / Fluticasone Furoate/Umeclidinium/Vilanterol
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT07282886 Comparator | Mar 2026 → Dec 2028 expected | asthma | University of Alabama at Birmingham | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fluticasone Furoate/Umeclidinium/Vilanterol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07282886 ↗ |
| Route | Inhaled | “Dry Powder Inhaler,100/62.5/25 mcg per inhalation” NCT07282886 ↗ |